Lupin gets USFDA approval to market antibacterial capsules
New Delhi: Drug firm Lupin said it has received final approval from the US health regulator to market its antibacterial Nitrofurantoin capsules used for treating urinary tract infections.
The approval from the United States Food and Drug Administration (USFDA) is to market the Nitrofurantoin capsules in the strengths of 50 mg and 100 mg, Lupin said in a statement.
The product is a generic version of Alvogen Malta Operations Ltd's Macrodantin capsules in the same strengths, it added.
The capsules are indicated for the treatment of urinary tract infections caused by certain bacteria, Lupin said.
As per the IQVIA MAT April 2018 data Nitrofurantoin capsules USP 50 mg and 100 mg had annual sales of around USD 27 million in the US, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd